SEHK:9966Biotechs
Why Alphamab Oncology (SEHK:9966) Is Up 9.2% After Priority Review For Anbenitamab In HER2 Breast Cancer
Alphamab Oncology recently reported half-year 2026 results showing CNY 271.24 million in sales and a net loss of CNY 40.46 million, while also securing Chinese priority review for multiple Anbenitamab new drug applications in HER2-positive breast cancer.
The acceptance of these Anbenitamab applications, backed by a head-to-head phase III trial in advanced HER2-positive breast cancer, marks a rare case where a bispecific antibody combination outperformed the long-standing THP standard regimen...